BioNTech sends $70M to another ADC partner to go up against Daiichi Sankyo in HER3
First, HER2. Now, HER3. That’s the plan of attack for BioNTech in its apparent bid to follow in the footsteps of antibody-drug conjugate leader Daiichi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
